Fluoropyrimidine-induced cardiotoxicity: outcomes and safety of chemotherapy reintroduction in a retrospective cohort study
Our findings suggest that fluoropyrimidine reintroduction-guided by multidisciplinary evaluation, cardiovascular management, and close monitoring-appears to have a favorable benefit/risk balance for selected patients.
Authors
- Pierre‐Yves Courand (ORCID: https://orcid.org/0000-0003-3199-7977)
- P. Lantelme
- Anissa C. Bouali (ORCID: https://orcid.org/0000-0003-0217-5747)
- M. Serraille
- Laurent François
- Océane Rea
- Justine Fort
- Claire Falandry
- Brahim Harbaoui
- Julien Péron
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Lyon College (US)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- Hôpital de la Croix-Rousse (FR)
- Hospices Civils de Lyon (FR)
- Laboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutrition (FR)
Publication Details
- Journal
- Supportive Care in Cancer
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1007/s00520-026-10531-2
- Citations
- 1
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 30.07